Loading clinical trials...
Loading clinical trials...
A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir
Conditions
Interventions
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Locations
1
United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
Start Date
November 1, 2014
Primary Completion Date
March 1, 2015
Completion Date
December 1, 2015
Last Updated
November 7, 2014
NCT01875588
NCT07071623
NCT04929028
NCT03087253
NCT07199335
NCT05419024
Lead Sponsor
St Stephens Aids Trust
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions